Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review

Abdul Rahman Jazieh, Reem Al Sudairy, Nada Abu-Shraie, Wafaa Al Suwairi, Mazen Ferwana, Mohammad H Murad

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Targeting epidermal growth factor receptors (EGFR) is an innovative approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation. However, the efficacy of these agents like erlotinib in patients without the mutation is not known. Methods: This systematic review included Phase III randomized clinical trials that compared single agent erlotinib to other management options in the setting of NSCLC with reported outcome data on patients with EGFR wild type (EGFRWT) tumors. Outcome data include overall survival (OS), progression free survival (PFS) and response rate (RR). Random effects meta-analysis was used to pool outcomes across studies. Results: Three studies met the inclusion criteria. These studies included a total of 2044 patients with outcome data on 674 patients with EGFRWT tumors (33%). Meta-analysis revealed a statistically significant improvement in OS with erlotinib (hazard ratio of 0.780; 95% confidence interval: 0.654-0.930, P = 0.006). Data were not available to perform PFS or RR analysis. The quality of this evidence is considered to be moderate to high. Conclusion: Our study revealed a significant benefit of erlotinib in patient with EGFRWT tumors compared with other approaches. These findings add another therapeutic option to patients generally considered difficult to treat.

Original languageEnglish (US)
Pages (from-to)204-208
Number of pages5
JournalAnnals of Thoracic Medicine
Volume8
Issue number4
DOIs
StatePublished - Oct 2013

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Meta-Analysis
Neoplasms
Phase III Clinical Trials
Mutation
Survival
Erlotinib Hydrochloride
Survival Rate
Randomized Controlled Trials
Outcome Assessment (Health Care)
Confidence Intervals
ErbB Receptors

Keywords

  • Epidermal growth factor
  • erlotinib
  • non-small cell lung cancer

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer : A systematic review. / Jazieh, Abdul Rahman; Al Sudairy, Reem; Abu-Shraie, Nada; Al Suwairi, Wafaa; Ferwana, Mazen; Murad, Mohammad H.

In: Annals of Thoracic Medicine, Vol. 8, No. 4, 10.2013, p. 204-208.

Research output: Contribution to journalArticle

Jazieh, Abdul Rahman ; Al Sudairy, Reem ; Abu-Shraie, Nada ; Al Suwairi, Wafaa ; Ferwana, Mazen ; Murad, Mohammad H. / Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer : A systematic review. In: Annals of Thoracic Medicine. 2013 ; Vol. 8, No. 4. pp. 204-208.
@article{e5fd07e0d19a4ee9b42bd9c572bc9a31,
title = "Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review",
abstract = "Background: Targeting epidermal growth factor receptors (EGFR) is an innovative approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation. However, the efficacy of these agents like erlotinib in patients without the mutation is not known. Methods: This systematic review included Phase III randomized clinical trials that compared single agent erlotinib to other management options in the setting of NSCLC with reported outcome data on patients with EGFR wild type (EGFRWT) tumors. Outcome data include overall survival (OS), progression free survival (PFS) and response rate (RR). Random effects meta-analysis was used to pool outcomes across studies. Results: Three studies met the inclusion criteria. These studies included a total of 2044 patients with outcome data on 674 patients with EGFRWT tumors (33{\%}). Meta-analysis revealed a statistically significant improvement in OS with erlotinib (hazard ratio of 0.780; 95{\%} confidence interval: 0.654-0.930, P = 0.006). Data were not available to perform PFS or RR analysis. The quality of this evidence is considered to be moderate to high. Conclusion: Our study revealed a significant benefit of erlotinib in patient with EGFRWT tumors compared with other approaches. These findings add another therapeutic option to patients generally considered difficult to treat.",
keywords = "Epidermal growth factor, erlotinib, non-small cell lung cancer",
author = "Jazieh, {Abdul Rahman} and {Al Sudairy}, Reem and Nada Abu-Shraie and {Al Suwairi}, Wafaa and Mazen Ferwana and Murad, {Mohammad H}",
year = "2013",
month = "10",
doi = "10.4103/1817-1737.118503",
language = "English (US)",
volume = "8",
pages = "204--208",
journal = "Annals of Thoracic Medicine",
issn = "1817-1737",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer

T2 - A systematic review

AU - Jazieh, Abdul Rahman

AU - Al Sudairy, Reem

AU - Abu-Shraie, Nada

AU - Al Suwairi, Wafaa

AU - Ferwana, Mazen

AU - Murad, Mohammad H

PY - 2013/10

Y1 - 2013/10

N2 - Background: Targeting epidermal growth factor receptors (EGFR) is an innovative approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation. However, the efficacy of these agents like erlotinib in patients without the mutation is not known. Methods: This systematic review included Phase III randomized clinical trials that compared single agent erlotinib to other management options in the setting of NSCLC with reported outcome data on patients with EGFR wild type (EGFRWT) tumors. Outcome data include overall survival (OS), progression free survival (PFS) and response rate (RR). Random effects meta-analysis was used to pool outcomes across studies. Results: Three studies met the inclusion criteria. These studies included a total of 2044 patients with outcome data on 674 patients with EGFRWT tumors (33%). Meta-analysis revealed a statistically significant improvement in OS with erlotinib (hazard ratio of 0.780; 95% confidence interval: 0.654-0.930, P = 0.006). Data were not available to perform PFS or RR analysis. The quality of this evidence is considered to be moderate to high. Conclusion: Our study revealed a significant benefit of erlotinib in patient with EGFRWT tumors compared with other approaches. These findings add another therapeutic option to patients generally considered difficult to treat.

AB - Background: Targeting epidermal growth factor receptors (EGFR) is an innovative approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation. However, the efficacy of these agents like erlotinib in patients without the mutation is not known. Methods: This systematic review included Phase III randomized clinical trials that compared single agent erlotinib to other management options in the setting of NSCLC with reported outcome data on patients with EGFR wild type (EGFRWT) tumors. Outcome data include overall survival (OS), progression free survival (PFS) and response rate (RR). Random effects meta-analysis was used to pool outcomes across studies. Results: Three studies met the inclusion criteria. These studies included a total of 2044 patients with outcome data on 674 patients with EGFRWT tumors (33%). Meta-analysis revealed a statistically significant improvement in OS with erlotinib (hazard ratio of 0.780; 95% confidence interval: 0.654-0.930, P = 0.006). Data were not available to perform PFS or RR analysis. The quality of this evidence is considered to be moderate to high. Conclusion: Our study revealed a significant benefit of erlotinib in patient with EGFRWT tumors compared with other approaches. These findings add another therapeutic option to patients generally considered difficult to treat.

KW - Epidermal growth factor

KW - erlotinib

KW - non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84885663957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885663957&partnerID=8YFLogxK

U2 - 10.4103/1817-1737.118503

DO - 10.4103/1817-1737.118503

M3 - Article

C2 - 24250733

AN - SCOPUS:84885663957

VL - 8

SP - 204

EP - 208

JO - Annals of Thoracic Medicine

JF - Annals of Thoracic Medicine

SN - 1817-1737

IS - 4

ER -